The Necessity of Cytoreductive Nephrectomy in @entity1 With XXXX Using Antiangiogenic Targeted Therapy After Interferon Alfa-2b.

@entity1 @entity1358 @entity669 @entity70811
BACKGROUND: Targeted therapy has improved the survival of @entity1 with metastatic @entity1358 . In the present study, we evaluated whether there was an effect of cytoreductive surgery on prognosis of @entity1 with metastatic @entity1358 using antiangiogenic @entity669 kinase inhibitor (TKI) agents. @entity1 AND METHODS: A total of 52 @entity1 with metastatic @entity1358 from Akdeniz University, Afyon Kocatepe University, and Medipol University participated in the study. All the @entity1 had received targeted antiangiogenic therapy after interferon alfa-2b. According to previous @entity70811 , the @entity1 were divided into 2 groups as @entity70811 (+) and @entity70811 (-). RESULTS: The @entity70811 (+) group was younger than the @entity70811 (-) group (P  < .001) and the hemoglobin levels were significantly higher in the @entity70811 (+) group (P  = .023). The median progression-free survival time from the date of starting TKIs were 8.5 and 3.0 months for the @entity70811 (+) and @entity70811 (-) groups, respectively (P  = .104). The median overall survival was 15.1 and 5.4 months for the @entity70811 (+) and @entity70811 (-) groups, respectively (P  = .034). CONCLUSION: We speculate that @entity70811 is still an important part of treatment modalities in @entity1 with metastatic @entity1358 in modern era targeted therapy, which is currently the best systemic therapy. However, the indications of @entity70811 might be limited to good-risk @entity1 with metastatic @entity1358 . Further randomized studies are warranted to clarify the necessity of @entity70811 in @entity1 with metastatic @entity1358 .
